diplomacy&development

The reports give deeper country-by-country specific dynamics and insights. The African Development Bank Group ( www.AfDB.org ) has launched  Country Focus Reports designed to deepen policy dialogue on the macroeconomic performance and outlook of individual countries and to act as an indispensable tool for policy makers, government and development partners. The reports, in line with the theme of the 2024  African Economic Outlook report (https://apo-opa.co/3SuB1Wu) titled, “Driving Africa’s Transformation: The Reform of the Global Financial Architecture,” give deeper country-by-country specific dynamics and insights. The African Economic Outlook report, issued annually, provides timely evidence and analysis on the continent’s growth, empowering African policymakers to make informed decisions. Growth performance and outlook vary across the 54 African countries of the report, reflecting differences in economic structure, commodity dependence, and policies. The 2024 reports assess the expe

The positive progress in domestic revenue mobilization since the start of the ECF program continued, reaching a record level of CFAF 80 billion during the first half of this year. The Central African Republic (CAR) continues to implement public finance management and governance reforms, despite the particularly difficult socio-economic context and significant financing needs; In the very short term, the main challenges concern the country's fuel supply and the control of budgetary risks; The implementation of the reforms planned under the CAR program supported by the Extended Credit Facility (ECF) remains the best path to macroeconomic stabilization in the medium term. An International Monetary Fund (IMF) team, led by Mr. Albert Touna Mama, visited Bangui from July 10 to 17, 2024, to take stock of the recent macroeconomic developments and the implementation of structural reforms, as well as to discuss the major budget allocations for the upcoming revised 2024 finance law. Mr. Touna

Burundian dentists and nurses had the opportunity to enhance their experience and update their knowledge by participating in the activities conducted by Turkish doctors. Turkish Cooperation and Coordination Agency (TİKA) and the Association of the Friends of Africa (TADD) organized an oral and dental health initiative in Burundi. Volunteer Turkish physicians provided free dental treatment to over 900 patients in the cities of Gitega and Bujumbura. As part of the program, free toothbrushes and toothpaste were distributed to patients, especially children. Patients also received training on oral and dental care. Burundian dentists and nurses had the opportunity to enhance their experience and update their knowledge by participating in the activities conducted by Turkish doctors. “GREAT CONTRIBUTION TO BURUNDI HEALTH SYSTEM” At the program’s closing, a press conference was held with significant participation from Burundian media, including Burundian National Radio and Television (RTNB). Sp

The Board of Executive Directors is responsible for the conduct of the general operations of the Bank, making decisions on loans, credits, grants, policies, and financial matters. A delegation of the World Bank Group’s (WBG) Board of Executive Directors (EDs) noted South Africa’s and Namibia’s progress in achieving their development goals and re-affirmed World Bank Group’s commitment to providing support. The 11 EDs and Alternate EDs were hosted by the World Bank and International Finance Corporation (IFC) country offices during their recent visit on July 7-13. The visit provided a platform to assess progress with projects and engage on the evolution of the World Bank Group’s relationship with the countries, from a knowledge-focused to a broader knowledge and financing partnership. EDs met government and business leaders, local stakeholders, and project beneficiaries, and experienced first-hand how the countries manage development priorities and challenges. South Africa and Namibia hav

The pace of technology adoption and digitization is accelerating in Africa, driving the need for highly secure data center facilities with exceptional levels of power availability, redundancy, and connectivity. Cofinity Group, Inc. (CGI) ( www.CofinityGroup.com ), a leader in the data center industry for over 15 years, is pleased to announce strategic Channel Partnership Agreements with leading data center providers in Africa including PAIX Data Centres, Rack Centre, Raxio, and Digital Realty which includes Digital Realty’s African entities; iColo, Teraco and Digital Realty Nigeria. Collectively, these data center providers operate in markets that represent over 75% of Sub-Saharan Africa's GDP across 11 countries. The pace of technology adoption and digitization is accelerating in Africa, driving the need for highly secure data center facilities with exceptional levels of power availability, redundancy, and connectivity.   “CGI is in a unique position to help enterprises secure and

La cadence de l’adoption technologique et de la numérisation s’accélère en Afrique et accroît la nécessité de disposer de centres de données hautement sécurisés avec des niveaux exceptionnels en termes de disponibilité, de redondance et de connectivité. Cofinity Group, Inc. (CGI) ( www.CofinityGroup.com ), chef de file des centres de données depuis plus de 15 ans, a le plaisir d’annoncer des accords de partenariats de distribution stratégiques avec les principaux fournisseurs de centres de données d’Afrique, notamment PAIX Data Centres, Rack Centre, Raxio, et Digital Realty, qui inclut les entités africaines de Digital Realty ; iColo, Teraco et Digital Realty Nigeria. Ensemble, ces fournisseurs de centres de données sont présents dans 11 marchés qui représentent plus de 75 % du PIB de l’Afrique subsaharienne. La cadence de l’adoption technologique et de la numérisation s’accélère en Afrique et accroît la nécessité de disposer de centres de données hautement sécurisés avec des niveaux e

According to the Demographic Health Indicators Survey (2015/16), the HIV prevalence rate in the general population 15-49 years is 2% and is higher amongst women. Angola faces a generalized Human Immunodeficiency Virus (HIV) epidemic, with sexual transmission being key to its spread. According to the Demographic Health Indicators Survey (2015/16), the HIV prevalence rate in the general population 15-49 years is 2% and is higher amongst women.  The HIV epidemic is mostly concentrated in urban areas, with the highest prevalence and incidence in the Eastern and Southern provinces of the country partly influenced by the porous borders with the Democratic Republic of Congo, including Lunda Norte, Lunda Sul and Malanje. According to UNAIDS (2022), around 310,000 people in Angola live with HIV/AIDS. However, antiretroviral treatment coverage is still insufficient, reaching only 49% of adults and 22% of children who need treatment. As part of a wider initiative to accelerate and strengthen join

   A high blood pressure medication which was trialled in a study led by The University of Western Australia has been approved for use in the United States. The US Food and Drug Administration approved TRYVIO, a drug to treat high blood pressure in patients who have shown resistance to other medications. Professor Markus Schlaich, Dobney Chair in Clinical Research at UWA’s Medical School, led the study of aprocitentan (sold under the name TRYVIO) and the results were published in the Lancet. However, it should be noted that TRYVIO is a drug not indicated for pregnant women for different reasons stated in following details: HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRYVIO safely and effectively. See full prescribing information for TRYVIO. TRYVIOTM (aprocitentan) tablets, for oral use Initial U.S. Approval: 2024   WARNING: EMBRYO–FETAL TOXICITY See full prescribing information for complete boxed warning. • TRYVIO can caus

  Un médicament contre l'hypertension artérielle qui a été testé dans le cadre d'une étude menée par The University of Western Australia a été approuvé pour une utilisation aux États-Unis. La Food and Drug Administration des États-Unis a approuvé TRYVIO, un médicament destiné à traiter l'hypertension artérielle chez les patients ayant montré une résistance à d'autres médicaments. Le professeur Markus Schlaich, titulaire de la chaire Dobney en recherche clinique à la faculté de médecine de l'UWA, a dirigé l'étude sur l'aprocitentan (vendu sous le nom de TRYVIO) et les résultats ont été publiés dans le Lancet. Il est toutefois à noter que TRYVIO est un médicament non indiqué chez la femme enceinte pour différentes raisons précisées ci-après : POINTS SAILLANTS DES INFORMATIONS DE PRESCRIPTION Ces faits saillants n'incluent pas toutes les informations nécessaires à l'utilisation TRYVIO de manière sûre et efficace. Voir les informations de prescription